Literature DB >> 14972646

Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia.

Eleftherios P Diamandis1, Andreas Scorilas, Tadaaki Kishi, Kaj Blennow, Liu-Ying Luo, Antoninus Soosaipillai, Alfred W Rademaker, Magnus Sjogren.   

Abstract

BACKGROUND: The role of various proteases in the pathogenesis of Alzheimer's disease is well documented. Recently, many members of the human tissue kallikrein family, a group of 15 secreted serine proteases, were found to be highly expressed in the central nervous system (CNS). Some of these enzymes can be measured in cerebrospinal fluid (CSF) by using ELISA-type methodologies.
METHODS: We quantified various kallikreins in CSF of 20 patients with Alzheimer's disease (AD), 16 patients with frontotemporal dementia (FTD), and 15 controls. We then correlated the levels of various kallikreins with presence of AD or FTD. Among all kallikreins measured, detectable levels in CSF were identified for kallikreins hK6, hK7, and hK10. Other tested kallikreins (hK5, hK8, hK11, and hK13) were unmeasurable. The most notable differences between kallikrein levels in CSF and the three groups of subjects were seen between controls and FTD patients for hK6 (decrease in FTD; P = 0.017), controls and FTD patients for hK7 (decrease in FTD; P < 0.001), and controls and AD patients for hK7 (decrease in AD; P = 0.019). In addition, significant differences were seen between FTD patients or control subjects and patients with AD patients for hK10 (increase in AD; P < 0.02). Approximately half of the AD patients had CSF hK10 levels that were higher than all patients with FTD except one and all control subjects except two. Various kallikrein concentrations in CSF were correlated, the strongest correlation seen between hK6 and hK7 (r(s) = 0.58). We also observed a statistically significant association between decreasing hK7 concentration in CSF and possession of one or two ApoE4 alleles (P = 0.014).
CONCLUSIONS: We demonstrate for the first time significant alterations of hK6, hK7, and hK10 concentration in CSF of patients with AD and FTD. Notably, all three kallikreins (hK6, hK7, and hK10) are decreased in CSF of FTD patients and hK10 is increased in CSF of AD patients, in comparison to control subjects. The possible connection between these enzymes and the pathogenesis and progression of AD and FTD needs to be further investigated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14972646     DOI: 10.1016/j.clinbiochem.2003.11.012

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  10 in total

1.  Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response.

Authors:  Michael Panos; George P Christophi; Moses Rodriguez; Isobel A Scarisbrick
Journal:  Biol Chem       Date:  2014-09       Impact factor: 3.915

Review 2.  New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family.

Authors:  Nashmil Emami; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2007-09-15       Impact factor: 6.603

3.  Kallikrein cascades in traumatic spinal cord injury: in vitro evidence for roles in axonopathy and neuron degeneration.

Authors:  Maja Radulovic; Hyesook Yoon; Nadya Larson; Jianmin Wu; Rachel Linbo; Joshua E Burda; Eleftherios P Diamandis; Sachiko I Blaber; Michael Blaber; Michael G Fehlings; Isobel A Scarisbrick
Journal:  J Neuropathol Exp Neurol       Date:  2013-11       Impact factor: 3.685

4.  A cardinal sin when researching neuropsin/KLK8: Thou shalt validate antibodies.

Authors:  Debomoy K Lahiri; Arpita Konar; Mahendra K Thakur; Bryan Maloney
Journal:  Alzheimers Dement       Date:  2017-07-18       Impact factor: 21.566

Review 5.  What have we learned about the kallikrein-kinin and renin-angiotensin systems in neurological disorders?

Authors:  Maria da Graça Naffah-Mazzacoratti; Telma Luciana Furtado Gouveia; Priscila Santos Rodrigues Simões; Sandra Regina Perosa
Journal:  World J Biol Chem       Date:  2014-05-26

Review 6.  Implication of the Kallikrein-Kinin system in neurological disorders: Quest for potential biomarkers and mechanisms.

Authors:  Amaly Nokkari; Hadi Abou-El-Hassan; Yehia Mechref; Stefania Mondello; Mark S Kindy; Ayad A Jaffa; Firas Kobeissy
Journal:  Prog Neurobiol       Date:  2018-01-31       Impact factor: 11.685

Review 7.  Involvement of Kallikrein-Related Peptidases in Normal and Pathologic Processes.

Authors:  Ana Carolina B Stefanini; Bianca Rodrigues da Cunha; Tiago Henrique; Eloiza H Tajara
Journal:  Dis Markers       Date:  2015-12-09       Impact factor: 3.434

8.  Loss of kallikrein-related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice.

Authors:  Kiwami Kidana; Takuya Tatebe; Kaori Ito; Norikazu Hara; Akiyoshi Kakita; Takashi Saito; Sho Takatori; Yasuyoshi Ouchi; Takeshi Ikeuchi; Mitsuhiro Makino; Takaomi C Saido; Masahiro Akishita; Takeshi Iwatsubo; Yukiko Hori; Taisuke Tomita
Journal:  EMBO Mol Med       Date:  2018-03       Impact factor: 12.137

9.  Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer's disease and associated with CSF-TAU and FDG-PET.

Authors:  Oliver Goldhardt; Inanna Warnhoff; Igor Yakushev; Ilijana Begcevic; Hans Förstl; Viktor Magdolen; Antoninus Soosaipillai; Eleftherios Diamandis; Panagiotis Alexopoulos; Timo Grimmer
Journal:  Transl Neurodegener       Date:  2019-08-27       Impact factor: 8.014

10.  Prognostic significance of multiple kallikreins in high-grade astrocytoma.

Authors:  Kristen L Drucker; Caterina Gianinni; Paul A Decker; Eleftherios P Diamandis; Isobel A Scarisbrick
Journal:  BMC Cancer       Date:  2015-08-01       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.